Japan Biotechnology Market Size, Share, and COVID-19 Impact Analysis, By Application (Bio-pharmacy, Bio-industries, Bio-services, Bio-agriculture and Bioinformatics), By Technology (Fermentation, Tissue Engineering and Regeneration, Polymerase Chain Reaction (PCR) Technology, Nanobiotechnology, Chromatography, Deoxyribonucleic Acid (DNA) Sequencing, and Cell Based Assay), and Japan Biotechnology Market Insights, Industry Trend, Forecasts to 2030.Industry: Healthcare
Japan Biotechnology Market Insights Forecasts to 2030
- The Japan Biotechnology Market Size was valued at USD 44.1 billion in 2021.
- The market is growing at a CAGR of 6.7% from 2022 to 2030
- The Japan market key players are actively advertising their products to stay in the competition and capture the attention of consumers all over the world.
The Japan Biotechnology Market Size was valued at USD 44.1 billion in 2021 and is expected to grow at a CAGR OF 6.7% from during the forecast period (2022-2030). One of the globe's largest biotechnology markets, Japan places a high priority on research and development. The Japanese government has aggressively encouraged the growth of the biotechnology sector through several initiatives, such as tax breaks and financing for R&D. The country's advanced healthcare system and the rising need for improved medications brought on by the high percentage of elderly people living there also contribute to the expansion of the biotechnology industry worldwide.
This research report categorizes the market of Japan Biotechnology Market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan Biotechnology Market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Japan Biotechnology Market.
Japan Biotechnology Market Report Coverage
|Market Size in 2022:||USD 44.1 billion|
|Forecast Period 2021-2030 CAGR:||CAGR of 6.7%|
|Historical Data for:||2020 to 2022|
|No. of Pages:||120|
|Tables, Charts & Figures:||93|
|Segments covered:||Japan Biotechnology By Application, By Technology|
|Companies Covered:||Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc, Daiichi Sankyo Co Ltd., Otsuka Holdings, Amino Up Co., Ltd, KOTAI Biotechnologies, Inc., Chiome Bioscience Inc, Japan Bioinformatics, TOKAI HIT, Artham Therapeutics, inc|
Get more details on this report -
Several driving factors are contributing to the growth of the Japan biotechnology market such as the geriatric population with a large percentage of overall 25% over the age of 65. This has led to an increased demand for healthcare services and innovative treatments for age-related diseases. The Japanese government's recent increases in healthcare spending have resulted in additional financing for biotechnology industry research and development, which is another important driver in Japan's economic growth. Moreover, the biotechnology sector has profited from Japan's reputation for innovative technology. The Japanese government has been actively promoting the growth of the biotechnology industry through various initiatives, including tax incentives and funding for research and development. Furthermore, Japan has an outstanding record for research and development thanks to its excellent research capacities, especially in sectors like pharmaceuticals and medical devices. This has led to a wealth of knowledge and expertise in the biotechnology industry. These driving factors are expected to continue contributing to the growth of the Japan biotechnology market during the forecast period.
The Japan Biotechnology Market is restraining growth due to, regulatory challenges, in that the biotechnology industry is heavily regulated in Japan, which can make it difficult for companies to bring new products to market. For smaller businesses, the regulatory process can be prohibitively expensive and time-consuming. Also, the market is highly competitive, with many established players in the industry. This can make it difficult for new companies to gain a foothold in the market. Additionally, creating new biotechnology goods can be costly, especially when it comes to sectors like medicine discovery and development. For smaller businesses or those without significant financial means, this may be a barrier to entry.
COVID 19 Impacts
The pandemic has led to a Japan race to develop vaccines against COVID-19, which has created new opportunities for companies involved in vaccine research and development. The demand for COVID-19 diagnostic tests has created new opportunities for companies involved in diagnostics and medical devices. The COVID-19 pandemic has disrupted many clinical trials, which has led to delays in the development of new biotechnology products. Also, the pandemic has caused disruptions to Japan supply chains, which has affected the availability of raw materials and other supplies needed for biotechnology research and development.
In 2021, bio-pharmacy is dominating the market with the largest market share over the forecast period.
Based on the Japan biotechnology market, the bio pharmacy held the largest market share during the forecast period due to increasing demand for drugs and medicine is driving the growth of the bio pharmacy segment in the biotechnology market. Also, several public and commercial businesses have been motivated to develop new medications and vaccines as a consequence of the rising prevalence of chronic diseases in the population.
In 2021, the nanobiotechnology segment is witnessing a higher growth rate during the forecast period
Based on the Japan biotechnology market, the technologies are bifurcated into fermentation, tissue engineering, and regeneration, polymerase chain reaction (PCR) technology, nanobiotechnology, chromatography, deoxyribonucleic acid (DNA) sequencing, and cell-based assay. Among these, the nanobiotechnology segment is expected to have a higher market share value during the forecast period owing to an increase in the development of novel drugs and rising spending by both public and private entities. Moreover, Theragnostic nanoparticles in nanobiotechnology have drawn challenges for providing precise diagnosis and customization of therapy choices for multiple disorders concurrently.
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Biotechnology Market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Takeda Pharmaceutical Co Ltd
- Astellas Pharma Inc
- Daiichi Sankyo Co Ltd.
- Otsuka Holdings
- Amino Up Co., Ltd
- KOTAI Biotechnologies, Inc.
- Chiome Bioscience Inc
- Japan Bioinformatics
- TOKAI HIT
- Artham Therapeutics, inc
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the Japan Biotechnology Market based on the below-mentioned segments:
Japan Biotechnology Market, By Application
Japan Biotechnology Market, By Technology
- Tissue Engineering and Regeneration,
- Polymerase Chain Reaction (PCR) Technology
- Deoxyribonucleic Acid (DNA) Sequencing,
- Cell Based Assay
Need help to buy this report?